Skip to main content

Table 1 Patient characteristics at ART initiation, and during follow-up (ART-LINC of IeDEA, 2008, n = 3,338)

From: Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings

Characteristics at ART initiation N  
Women (%) 2,139 (64.1)
Median age (IQR*) 34.0 (30–41)
Clinical stage (%)   
 WHO I/II or CDC A/B 1,078 (32.3)
 WHO III 977 (29.3)
 WHO IV or AIDS 1,019 (30.5)
 Unknown 264 (7.9)
Year of starting ART (%)   
 1997 to 2001 351 (10.5)
 2002 to 2003 917 (27.5)
 2004 to 2005 1,629 (48.8)
 2006 to 2007 441 (13.2)
First ART regimen (%)   
 2NRTIs + 1NNRTI 3,205 (96.0)
 2NRTIs + 1PI 133 (4.0)
Median CD4 cell count (IQR) 107 (46–179)
HIV-RNA (%)   
 [500–10,000[ copies/mL 170 (5.1)
 ≥10,000 copies/mL 1,942 (58.2)
Unknown 1,226 (36.7)
Characteristics 6 months after ART initiation   
Median CD4 cell count (IQR) 228 (158–325)
HIV-RNA (%)   
 <500 copies/mL 3,038 (91.0)
 [500–10,000[ copies/mL 155 (4.6)
 ≥10,000copies/mL 145 (4.4)
Characteristics 12 months after ART initiation   
Median CD4 cell count (IQR) 276 (192–383)
HIV-RNA (%)   
 <500 copies/mL 2,969 (89.0)
 [500–10,000[ copies/mL 187 (5.6)
 ≥10,000 copies/mL 182 (5.4)
Median follow-up in years (IQR) 1.6 (1.2-2.4)
Median number of CD4 measurements (IQR) 2 (2–3)
Deaths at M18 (%) 18 (0.5)
Lost to follow-up at M18 (%) 325 (9.7)
  1. * IQR = interquartile range.
  2. ART: Antiretroviral treatment.
  3. NNRTI: Non nucleoside reverse transcriptase inhibitor.
  4. NRTI: Nucleoside reverse transcriptase inhibitor.
  5. PI: Protease inhibitor.